ModernaRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
Moderna (MRNA) reported revenue of $145.00M in Q2 2026.
Q1 2017-Q2 2026(All available data)
Q1 2017-Q2 2026(All available data)
ModernamRNA platform company. Spikevax, mNEXSPIKE, mRESVIA, and mFLUSIVA (FDA 5 Aug 2026, adults 50+) on market. FY 2025 revenue $1.94B. Pipeline swing factor: intismeran autogene with Merck after CMV and norovirus Phase 3 misses.
Moderna (MRNA) is a Biotechnology company. mRNA platform company. Spikevax, mNEXSPIKE, mRESVIA, and mFLUSIVA (FDA 5 Aug 2026, adults 50+) on market. FY 2025 revenue $1.94B. Pipeline swing factor: intismeran autogene with Merck after CMV and norovirus Phase 3 misses. It was founded in 2010, is headquartered in Cambridge, MA and employs about 5,800 people.
Track Moderna's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 19, 2026.
Sterling groups Moderna in the Vaccines sector, alongside GSK (GSK), Pfizer (PFE), Merck & Co. (MRK), Sanofi (SNY), BioNTech (BNTX) and AstraZeneca (AZN).
If you are researching Moderna, also look at GSK (GSK), Pfizer (PFE) and Merck & Co. (MRK). You can compare all of them side by side or browse the full Vaccines sector on Sterling.